These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18008346)

  • 1. Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
    Filho AL; Baltazar F; Bedrossian C; Michael C; Schmitt FC
    Diagn Cytopathol; 2007 Dec; 35(12):786-91. PubMed ID: 18008346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma.
    Niki T; Iba S; Yamada T; Matsuno Y; Enholm B; Hirohashi S
    J Pathol; 2001 Apr; 193(4):450-7. PubMed ID: 11276003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
    Park HR; Min K; Kim HS; Jung WW; Park YK
    Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
    Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
    J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors.
    Partanen TA; Alitalo K; Miettinen M
    Cancer; 1999 Dec; 86(11):2406-12. PubMed ID: 10590384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis.
    Mogi A; Nabeshima K; Hamasaki M; Uesugi N; Tamura K; Iwasaki A; Shirakusa T; Iwasaki H
    Pathol Int; 2009 Dec; 59(12):874-9. PubMed ID: 20021613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retiform hemangioendotheliomas usually do not express D2-40 and VEGFR-3.
    Parsons A; Sheehan DJ; Sangueza OP
    Am J Dermatopathol; 2008 Feb; 30(1):31-3. PubMed ID: 18212541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
    Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
    Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
    Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
    Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of vascular endothelial growth factor in malignant mesothelioma.
    Aoe K; Hiraki A; Tanaka T; Gemba K; Taguchi K; Murakami T; Sueoka N; Kamei T; Ueoka H; Sugi K; Yoshino T; Kishimoto T
    Anticancer Res; 2006; 26(6C):4833-6. PubMed ID: 17214348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Kit is not expressed in malignant mesothelioma.
    Horvai AE; Li L; Xu Z; Kramer MJ; Jablons DM; Treseler PA
    Mod Pathol; 2003 Aug; 16(8):818-22. PubMed ID: 12920227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podoplanin as a marker for mesothelioma.
    Kimura N; Kimura I
    Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
    Kahlos K; Pääkkö P; Kurttila E; Soini Y; Kinnula VL
    Br J Cancer; 2000 Mar; 82(5):1022-9. PubMed ID: 10737384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma.
    Clarijs R; Schalkwijk L; Hofmann UB; Ruiter DJ; de Waal RM
    Cancer Res; 2002 Dec; 62(23):7059-65. PubMed ID: 12460927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
    O'Kane SL; Cawkwell L; Campbell A; Lind MJ
    Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
    Onofri C; Losa M; Uhl E; Stalla GK; Renner U
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
    Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
    Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
    Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
    Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.